Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells
The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound hea...
Gespeichert in:
Veröffentlicht in: | Oncology reports 2023-05, Vol.49 (5), p.1, Article 93 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 5 |
container_start_page | 1 |
container_title | Oncology reports |
container_volume | 49 |
creator | Souza, Deborah S Macheroni, Carla Vicente, Carolina M Cavalheiro, Renan P Campo, Vanessa L Porto, Catarina S |
description | The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells. |
doi_str_mv | 10.3892/or.2023.8530 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10086566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A749550298</galeid><sourcerecordid>A749550298</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-dfb629d832a132415b2cf36239a286c0bca3b3eba617a9a0d0b19e950cc300f3</originalsourceid><addsrcrecordid>eNptks9rFTEQxxdRbK3ePMuCIB7c5yTZZDenUmq1QsFLBW8hm519L2VfsiZZobf-C_0X-5eYtT_sEwkkk8lnJplvpiheE1ixVtKPPqwoULZqOYMnxT5pJKlozcjTbAMlFWP8x17xIsYLANqAkM-LPSakgFbU-4U-iSn4NboyoMEp-RCztZ5HnbBc6xFNsu7m6pqV1pXa9X_YvLeuxwnz5FL56Xt2kJqXU_AxLYFGO4OhNDiO8WXxbNBjxFd360Fx_vnk_Pi0Ovv25evx0VllOCGp6odOUNm3jGrCaE14R83ABGVS01YY6IxmHcNOC9JoqaGHjkiUHIxhAAM7KA5v005zt8Xe5IcFPaop2K0Ol8prq3ZPnN2otf-lCGQluBA5w_u7DMH_nDEmtbVxKUE79HNUNCvLRENrmdG3_6AXfg4ul6doC21dS06av9Sio7Ju8PlisyRVR01GOFDZZmr1HyqPHrfWeIeDzf6dgHePAjaox7SJfpyT9S7ugh9uQZP_JQYcHtQgoJbeUT6opXfU0jsZf_NYwQf4vlnYb9sfwMM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2808449517</pqid></control><display><type>article</type><title>Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Souza, Deborah S ; Macheroni, Carla ; Vicente, Carolina M ; Cavalheiro, Renan P ; Campo, Vanessa L ; Porto, Catarina S</creator><creatorcontrib>Souza, Deborah S ; Macheroni, Carla ; Vicente, Carolina M ; Cavalheiro, Renan P ; Campo, Vanessa L ; Porto, Catarina S</creatorcontrib><description>The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2023.8530</identifier><identifier>PMID: 36960864</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Androgens ; Antibodies ; Apoptosis ; Biological products industry ; Cancer cells ; Cancer therapies ; Cell culture ; Estradiol ; Estradiol - pharmacology ; Estrogen Receptor alpha - metabolism ; Estrogen Receptor beta - genetics ; Estrogen Receptor beta - metabolism ; Estrogens ; Experiments ; Galectin 3 ; Humans ; Kinases ; Laboratories ; Male ; Metastasis ; Phenols ; Photographic industry ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - metabolism ; Proteins ; Receptors, Estrogen ; Transcription factors ; Wound healing</subject><ispartof>Oncology reports, 2023-05, Vol.49 (5), p.1, Article 93</ispartof><rights>COPYRIGHT 2023 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2023</rights><rights>Copyright: © Souza et al. 2023</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-dfb629d832a132415b2cf36239a286c0bca3b3eba617a9a0d0b19e950cc300f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,27933,27934</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36960864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Souza, Deborah S</creatorcontrib><creatorcontrib>Macheroni, Carla</creatorcontrib><creatorcontrib>Vicente, Carolina M</creatorcontrib><creatorcontrib>Cavalheiro, Renan P</creatorcontrib><creatorcontrib>Campo, Vanessa L</creatorcontrib><creatorcontrib>Porto, Catarina S</creatorcontrib><title>Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells.</description><subject>Androgens</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Biological products industry</subject><subject>Cancer cells</subject><subject>Cancer therapies</subject><subject>Cell culture</subject><subject>Estradiol</subject><subject>Estradiol - pharmacology</subject><subject>Estrogen Receptor alpha - metabolism</subject><subject>Estrogen Receptor beta - genetics</subject><subject>Estrogen Receptor beta - metabolism</subject><subject>Estrogens</subject><subject>Experiments</subject><subject>Galectin 3</subject><subject>Humans</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Male</subject><subject>Metastasis</subject><subject>Phenols</subject><subject>Photographic industry</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Proteins</subject><subject>Receptors, Estrogen</subject><subject>Transcription factors</subject><subject>Wound healing</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptks9rFTEQxxdRbK3ePMuCIB7c5yTZZDenUmq1QsFLBW8hm519L2VfsiZZobf-C_0X-5eYtT_sEwkkk8lnJplvpiheE1ixVtKPPqwoULZqOYMnxT5pJKlozcjTbAMlFWP8x17xIsYLANqAkM-LPSakgFbU-4U-iSn4NboyoMEp-RCztZ5HnbBc6xFNsu7m6pqV1pXa9X_YvLeuxwnz5FL56Xt2kJqXU_AxLYFGO4OhNDiO8WXxbNBjxFd360Fx_vnk_Pi0Ovv25evx0VllOCGp6odOUNm3jGrCaE14R83ABGVS01YY6IxmHcNOC9JoqaGHjkiUHIxhAAM7KA5v005zt8Xe5IcFPaop2K0Ol8prq3ZPnN2otf-lCGQluBA5w_u7DMH_nDEmtbVxKUE79HNUNCvLRENrmdG3_6AXfg4ul6doC21dS06av9Sio7Ju8PlisyRVR01GOFDZZmr1HyqPHrfWeIeDzf6dgHePAjaox7SJfpyT9S7ugh9uQZP_JQYcHtQgoJbeUT6opXfU0jsZf_NYwQf4vlnYb9sfwMM</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Souza, Deborah S</creator><creator>Macheroni, Carla</creator><creator>Vicente, Carolina M</creator><creator>Cavalheiro, Renan P</creator><creator>Campo, Vanessa L</creator><creator>Porto, Catarina S</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230501</creationdate><title>Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells</title><author>Souza, Deborah S ; Macheroni, Carla ; Vicente, Carolina M ; Cavalheiro, Renan P ; Campo, Vanessa L ; Porto, Catarina S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-dfb629d832a132415b2cf36239a286c0bca3b3eba617a9a0d0b19e950cc300f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Androgens</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Biological products industry</topic><topic>Cancer cells</topic><topic>Cancer therapies</topic><topic>Cell culture</topic><topic>Estradiol</topic><topic>Estradiol - pharmacology</topic><topic>Estrogen Receptor alpha - metabolism</topic><topic>Estrogen Receptor beta - genetics</topic><topic>Estrogen Receptor beta - metabolism</topic><topic>Estrogens</topic><topic>Experiments</topic><topic>Galectin 3</topic><topic>Humans</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Male</topic><topic>Metastasis</topic><topic>Phenols</topic><topic>Photographic industry</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Proteins</topic><topic>Receptors, Estrogen</topic><topic>Transcription factors</topic><topic>Wound healing</topic><toplevel>online_resources</toplevel><creatorcontrib>Souza, Deborah S</creatorcontrib><creatorcontrib>Macheroni, Carla</creatorcontrib><creatorcontrib>Vicente, Carolina M</creatorcontrib><creatorcontrib>Cavalheiro, Renan P</creatorcontrib><creatorcontrib>Campo, Vanessa L</creatorcontrib><creatorcontrib>Porto, Catarina S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Souza, Deborah S</au><au>Macheroni, Carla</au><au>Vicente, Carolina M</au><au>Cavalheiro, Renan P</au><au>Campo, Vanessa L</au><au>Porto, Catarina S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>49</volume><issue>5</issue><spage>1</spage><pages>1-</pages><artnum>93</artnum><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>36960864</pmid><doi>10.3892/or.2023.8530</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1021-335X |
ispartof | Oncology reports, 2023-05, Vol.49 (5), p.1, Article 93 |
issn | 1021-335X 1791-2431 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10086566 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Androgens Antibodies Apoptosis Biological products industry Cancer cells Cancer therapies Cell culture Estradiol Estradiol - pharmacology Estrogen Receptor alpha - metabolism Estrogen Receptor beta - genetics Estrogen Receptor beta - metabolism Estrogens Experiments Galectin 3 Humans Kinases Laboratories Male Metastasis Phenols Photographic industry Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - metabolism Proteins Receptors, Estrogen Transcription factors Wound healing |
title | Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T23%3A39%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estrogen%20receptors%20regulate%20galectin%E2%80%913%20in%20androgen%E2%80%91independent%20DU%E2%80%91145%20prostate%20cancer%20cells&rft.jtitle=Oncology%20reports&rft.au=Souza,%20Deborah%20S&rft.date=2023-05-01&rft.volume=49&rft.issue=5&rft.spage=1&rft.pages=1-&rft.artnum=93&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2023.8530&rft_dat=%3Cgale_pubme%3EA749550298%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2808449517&rft_id=info:pmid/36960864&rft_galeid=A749550298&rfr_iscdi=true |